Envestnet Asset Management
TSHA icon

Envestnet Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Envestnet Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
37,314
+3,660
+11% +$21.7K ﹤0.01% 4525
2026
Q1 		$150K Buy
33,654
+13,476
+67% +$62.7K ﹤0.01% 4565
2025
Q4 		$111K Buy
+20,178
New +$98K ﹤0.01% 4359

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Envestnet Asset Management's TSHA Position: Q2 2026 in Review

Envestnet Asset Management increased its Taysha Gene Therapies (TSHA) stake by 11% in Q2 2026, buying an estimated $21.7K and bringing the position to 37,314 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #4525.

Envestnet Asset Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Envestnet Asset Management held 37,314 shares of Taysha Gene Therapies worth $254K as of Q2 2026.
  • Envestnet Asset Management bought 3,660 Taysha Gene Therapies shares in Q2 2026, an estimated $21.7K.
  • Taysha Gene Therapies made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4525 holding.
  • Envestnet Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.